Research
Hormonal
Tirzepatide is in phase 3 development for adults with obesity or overweight with weight-related comorbidity.
Practitioners should be aware of Tirzepatide's potential for treating obesity in clinical settings.
StrongSupportsmedium confidence
Tirzepatide is in phase 3 development for adults with obesity or overweight with weight-related comorbidity.
Why this rating
The claim is based on the status of clinical trials, which is a reliable form of evidence.
Source
Tirzepatide: Revolutionary Drug in Management of “Diabesity”
Vansh Chouhan et al. · International Journal of Medical and Dental Sciences · 2022
DOI 10.18311/ijmds/2022/636
other
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →